Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly.

Abstract

Acromegaly is a rare chronic, systemic disorder caused by excessive growth hormone (GH) secretion from a somatotroph pituitary adenoma. GH hypersecretion leads to overproduction of insulin-like growth factor-1 (IGF-1), which contributes to the somatic overgrowth, physical disfigurement, onset of multiple systemic comorbidities, reduced quality of life (QoL) and premature mortality of uncontrolled patients. Somatostatin receptor ligands, dopamine agonists and a GH receptor antagonist are currently available for medical therapy of acromegaly. The main aim of treatment is biochemical normalisation, defined as age-normalised serum IGF-1 values and random GH levels <1.0 μg/L. However, there is an increasing evidence suggesting that achieving biochemical control does not always decrease the burden of disease-related comorbidities and/or improve patients' QoL. This lack of correlation between biochemical and clinical control can be due to both disease duration (late diagnosis) or to the peculiarity of a given comorbidity. Herein we conducted ad hoc literature searches in order to find the most recent and relevant reports on biochemical and clinical disease control during medical treatment of acromegaly. Particularly, we analyse and describe the relationship between biochemical, as well as clinical disease control in patients with acromegaly receiving medical therapy, with a focus on comorbidities and QoL. In conclusion, we found that current literature data seem to indicate that clinical disease control (besides biochemical control), encompassing clinical signs and symptoms, comorbidities and QoL, emerge as a primary focus of acromegaly patient management.

• Authors: Federico Gatto, Claudia Campana, Francesco Cocchiara, Giuliana Corica, Manuela Albertelli, Mara Boschetti, Gianluigi Zona, Diego Criminelli, Massimo Giusti, Diego Ferone
• Journal: Reviews in endocrine & metabolic disorders (Rev Endocr Metab Disord) Vol. 20 Issue 3 Pg. 365-381 (09 2019) ISSN: 1573-2606 [Electronic] Germany
• PMID: 31342434 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Topics

• Acromegaly (physiopathology)
• Animals
• Comorbidity
• Female
• Humans
• Male
• Quality of Life